10-Q · May 15, 2026
BioAtla, Inc. demonstrated significant financial improvement in Q4 2025, reporting revenues of $2 million, surpassing the expectation of $700,000, and achieving an EPS of -$0.16, much better than the estimated -$0.36.…
Earnings analysis · 10-Q
BCAB earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The 10-Q shows a substantially narrowed six-month net loss of $5.9 million versus $34.0 million a year earlier, but the improvement reflects cost conservation rather than commercial growth; the filing provides no…
Read full summary
The 10-Q shows a substantially narrowed six-month net loss of $5.9 million versus $34.0 million a year earlier, but the improvement reflects cost conservation rather than commercial growth; the filing provides no quantitative revenue, EPS, margin or free-cash-flow data in the extracted text. Financial risk is acute, with only approximately $1.5 million of cash at June 30, 2026 and management stating that funds are insufficient for at least 12 months of operations, raising substantial doubt about going concern. The newly formalized strategic-options process, approximately 70% workforce reduction and unresolved Nasdaq delisting review materially increase execution and financing risk.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Six-Month Loss Narrowed
Six-month net loss improved to $5.9 million from $34.0 million in the six months ended June 30, 2025, a $28.1 million reduction. Management attributes the expected near-term expense decline partly to completion of certain clinical trials and restructuring.
-
$250,000 License Proceeds
The company amended its EXUMA license agreement on August 12, 2026, receiving an Amendment Pay-Off Amount of $250,000 within 2 business days; the amendment satisfies all royalty obligations and makes the license royalty-free and fully paid-up.
-
Controls Remained Effective
Management stated that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes during the quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
What to watch
-
Strategic Alternatives May Fail
The company has initiated a formal process to explore asset sales, licensing transactions, strategic partnerships and other corporate transactions, with no set timetable. The associated restructuring included an approximately 70% workforce reduction, creating execution and retention risk.
-
Severe Liquidity Shortfall
Cash and cash equivalents were approximately $1.5 million as of June 30, 2026, and management stated that this amount is not sufficient to fund ongoing operations for at least 12 months from issuance of the financial statements. The company reported a $5.9 million net loss for the six months ended June 30, 2026 and substantial doubt about its ability to continue as a going concern.
-
Nasdaq Delisting Risk
Nasdaq’s Listing Council review remains ongoing after a February 6, 2026 delist determination based on noncompliance with the minimum bid-price and stockholders’ equity requirements. Although the company had evidenced at least $35 million of market value of listed securities for 69 consecutive trading days, continued listing is not assured.
-
Clinical Safety Events
Clinical safety risk remains material: in the BA3182 trial, the company reported a grade 2 colitis event followed by patient withdrawal, hospice transfer and death attributed to colitis. The filing also reports cytokine release syndrome, diarrhea and transient liver-enzyme and bilirubin elevations in BA3182.
-
Dilution and Limited Warrant Proceeds
The April 6, 2026 share consolidation triggered warrant repricing to $4.35, which management states will substantially limit proceeds from exercise of the outstanding warrants. Future equity or convertible-debt financing may also dilute existing holders.
-
China Supply-Chain Exposure
The company relies on third parties and China-linked suppliers for development and manufacturing activities, including agreements with WuXi Biologics and WuXi XDC Hong Kong. The filing states that the BIOSECURE Act was signed into law in December 2025 and may require alternative contract manufacturing relationships if applicable restrictions affect current suppliers.
Management's outlook
No numeric revenue or EPS guidance was provided in the extracted 10-Q text; management discusses strategic alternatives and liquidity risk but does not provide a quantitative outlook.
Earlier filings 4
10-K · April 29, 2026
BioAtla, Inc. displayed a significant improvement in financial performance in Q4 2025, achieving revenue of $2,000,000, surpassing the consensus estimate of $700,000, and reporting an EPS of -$0.16 against an estimate…
10-K · March 31, 2026
BioAtla describes a platform strategy built around its proprietary CAB antibody technology and a diversified clinical-stage pipeline (BA3182, BA3021/ozuriftamab vedotin, BA3011, BA3071) with broad IP protection (868…
10-Q · November 13, 2025
BioAtla reported $0 of collaboration revenue for Q3 (vs $11,000 in Q3 2024), a net loss of $15,778 (-$0.27 per share) for the quarter and a nine-month net loss of $49,823 (-$0.85 per share). Cash fell sharply to $8,320…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.